LLY vs MRK
Lilly (Eli) and Merck & Co., both Healthcare
Lilly (Eli) is the larger company at $980B against $281B. On trailing earnings LLY is the cheaper of the two at a P/E of 39.5 against 115.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year MRK returned +83% against +55% for LLY. The RyuScore puts MRK ahead, 78 against 63 out of 100.
| Figure | LLY | MRK |
|---|---|---|
| Last close | $1179 | $146 |
| Market cap | $980B | $281B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 39.5 | 115.5 |
| Dividend yield | 0.5% | 2.3% |
| 1-year return | +55% | +83% |
| 5-year return | +418% | +132% |
| RyuScoresector-relative, 1–10 | 63/100 | 78/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Lilly (Eli)
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Merck & Co.
Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.